Skip to content
Screener

Nuvation Bio NUVB Total Operating Expenses

Total Operating Expenses at other companies

Immunome logo
ImmunomeIMNM
$59.33M+24.7%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$30.93M-27.9%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$46.11M-30.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$137M-18.5%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$195.21M+192%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.15B+168%
Enterprise value$1.9B+211%
P/S12.6×-43.1×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Cost of collaboration and license agreements revenue8,5602,40414,1764,498
Research and development30,66127,36265,70851,963
Selling, general and administrative42,59138,48480,90073,877
Total costs and expenses82,72368,422162,070130,510
Loss from operations(51,036)(63,589)(47,155)(122,593)
Other income (expense):
Interest income4,5964,7809,70410,101
Interest expense(6,759)(421)(13,467)(475)

Item 1. Financial Statements.

FAQ

What is Nuvation Bio's total operating expenses?
Nuvation Bio (NUVB) reported total operating expenses of $82.72M in Q2 2026.
How has Nuvation Bio's total operating expenses changed year-over-year?
Nuvation Bio's total operating expenses increased by 20.9% year-over-year, from $68.42M to $82.72M.
What is the long-term trend for Nuvation Bio's total operating expenses?
Over 4 years (2021 to 2025), Nuvation Bio's total operating expenses has grown at a 31.7% compound annual growth rate (CAGR), from $93.32M to $280.64M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Nuvation Bio's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude